

RLL-263US  
Application No. 10/616,240  
Singh et al.

Page 2

**Amendments to the Claims:**

1.-16. (Canceled)

17. (Currently Amended) An oral dosage form comprising:

about 7% to 25% by weight of modafinil particles ~~have~~ having diameters greater than 220  $\mu\text{m}$ ;

about 93% to 75% by weight of modafinil particles ~~have~~ having diameters less than 220  $\mu\text{m}$ ,

wherein about 90% of the particles having diameters size less than 220  $\mu\text{m}$  are further characterized in that they have diameters less than about 41  $\mu\text{m}$ , and about 50% of the particles having diameters size less than 220  $\mu\text{m}$  are further characterized in that they have diameters less than about 21  $\mu\text{m}$ .

18. (Original) The oral dosage form according to claim 17 wherein about 7% by weight of the modafinil particles have diameters greater than 220  $\mu\text{m}$  and about 93% by weight of the modafinil particles have diameters less than 220  $\mu\text{m}$ .

19. (Original) The oral dosage form according to claim 17 wherein about 10% by weight of the modafinil particles have diameters greater than 220  $\mu\text{m}$  and about 90% by weight of the modafinil particles have diameters less than 220  $\mu\text{m}$ .

20. (Original) The oral dosage form according to claim 17 wherein about 15% by weight of the modafinil particles have diameters greater than 220  $\mu\text{m}$  and about 85% by weight of the modafinil particles have diameters less than 220  $\mu\text{m}$ .

21. (Original) The oral dosage form according to claim 17 wherein the specific surface area of the modafinil particles is at least 0.2  $\text{m}^2/\text{gm}$ .

22. (Original) The oral dosage form according to claim 17 wherein the dosage form releases at least 75% of the modafinil in about 45 minutes.

23. (Original) The oral dosage form according to claim 17 wherein the dosage form comprises a tablet or capsule.

RLL-263US  
Application No. 10/616,240  
Singh et al.

Page 3

24. (Original) The oral dosage form according to claim 17 further comprising one or more pharmaceutically acceptable excipients.

25. (Currently Amended) The oral dosage form according to claim 24 wherein the one or more pharmaceutically acceptable excipients comprises one or more of binders, diluents, disintegrants, surfactants, lubricants, glidants, and coloring agents.

26.-35. (Canceled)

36. (Currently Amended) An oral dosage form of modafinil comprising an intragranular and an extragranular portion:

an the intragranular portion comprising about 7% to 25% by weight of modafinil particles having diameters greater than 220  $\mu$ m, about 93% to 75% by weight of modafinil particles having diameters less than 220  $\mu$ m, wherein about 90% of the particles having diameters size less than 220  $\mu$ m are further characterized in that they have diameters less than about 41  $\mu$ m, and about 50% of the particles having diameters size less than 220  $\mu$ m are further characterized in that they have diameters less than about 21  $\mu$ m, and

one or more pharmaceutically acceptable excipients; and

an extragranular portion comprising one or more pharmaceutically acceptable excipients.

37. (Original) The oral dosage form according to claim 36 wherein the oral dosage form releases one or more of between 48% and 81% of the modafinil within 15 minutes, between 68% and 87% of the modafinil within 30 minutes, between 76% and 95% of the modafinil within 45 minutes, between 84% and 97% of the modafinil within 60 minutes, and between 89% and 98% of the modafinil within 90 minutes.

38. (Original) The oral dosage form according to claim 37 wherein the modafinil is released in a USP Apparatus II, in 900 ml of water, and stirred at 50 rpm.

39. (Original) The oral dosage form according to claim 36 wherein the oral dosage form is provided with labeling for one or more of wakefulness promotion, to improve

**RLL-263US**  
**Application No. 10/616,240**  
**Singh et al.**

**Page 4**

wakefulness in patients with excessive daytime sleepiness associated with narcolepsy,  
and idiopathic hypersomnia.